Myrio Therapeutics Announces Collaboration to Advance Solid Tumor T cell Immunotherapeutics
Myrio Therapeutics announced a collaborative research partnership with the University of Pennsylvania’s Perelman School of Medicine and NYU Langone Health.
The partnership aims to accelerate the development of next generation solid tumor T cell immunotherapeutics, combining expertise in peptide HLA (pHLA) binder discovery, bispecific T-cell engager development and cell immunotherapies.
The tri-party agreement brings together complementary expertise to overcome barriers to effective and durable immunotherapies through three core pillars.
- Combining strengths to generate deeper insights into mechanisms
- Exploring the therapeutic potential of these technologies
Author's summary: Myrio Therapeutics collaborates with leading research institutions.
More News
- Policy Brief: Internet Shutdowns - Internet Society
- Telcos and ISPs: The time to prioritise cyber security is now
- The Angel Ball Honors Tina Knowles
- Meet Mt Eden’s newest Italian joint, serving hearty pizza and pasta that's comfort food at its best
- Former Cwmbran High School pupil shortlisted for Cardiff Business Awards
- Nicole Kidman thriving while Keith Urban struggles after split
- Dortmund reach last 16 after penalty shootout
- Looking back: Local ghost legends
- Nick Offerman and Lee K. Buchanan Close Out Arts and Humanities Day with a Love Letter to Carpentry, Family, and the Pursuit of Hands-On Work in the Digital Age
- Dry Eye Disease Still Lacks Effective Treatment Options | Managed Healthcare Executive